$24.06-0.80 (-3.22%)
Seaport Therapeutics, Inc.
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$27.54M↓ | -$16.18M |
| Net Income | -$25.41M↓ | -$13.13M |
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using...

Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.
What Seaport Therapeutics' latest stock move signals for investors Seaport Therapeutics (SPTX) drew attention after a 10.2% 1 day move left the stock at $19.84 and a market value of about $1.05b, prompting fresh questions about how investors are sizing up its clinical pipeline. See our latest analysis for Seaport Therapeutics. The 10.22% 1 day share price return has also set the tone for the year to date, with the same 10.22% share price return indicating very early momentum in Seaport...